tetano
Editor, Senior Moderator
Biomed Res Int
. 2020 Aug 12;2020:3280908.
doi: 10.1155/2020/3280908. eCollection 2020.
Changes in the Clinical Characteristics of 62 Patients Who Died from Coronavirus Disease 2019
Jingli Chen[SUP] 1 [/SUP], Jishi Ye[SUP] 2 [/SUP], Hui Li[SUP] 3 [/SUP], Zhongyuan Xia[SUP] 2 [/SUP], Hong Yan[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Since the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in December 2019 in Wuhan, China, the virus has spread to other parts of China and across the world. Although a few studies have assessed the clinical course of coronavirus disease 2019 (COVID-19), the changes in clinical characteristics during disease progression remain unclear.
Methods: We retrospectively analyzed the clinical characteristics of 62 patients who died from COVID-19 at the Central Hospital of Wuhan between January 26 and February 17, 2020. We compared the clinical features on admission and at the last follow-up before death.
Results: Of the 62 patients with COVID-19, 41 (66%) patients were male, and 21 (34%) were female. The median age was 72 years (interquartile range (IQR), 54-88), and 45 (72.5%) patients had preexisting conditions. The median time from symptom onset to the first visit at the clinic was three days, while the median time from symptom onset to death was 18.5 days. During disease progression, the amounts of arterial gases worsened, and liver, renal, and heart dysfunction was observed. Due to the cytokine storm, infection-related biomarkers, including lactic acid, C-reactive protein, and interleukine-6, gradually worsened during hospitalization.
Conclusion: Our findings suggest that during hospitalization, many COVID-19 patients experienced multiple organ dysfunction and cytokine storm. The time from symptom onset to death was only 18.5 days, highlighting the disease's rapid progression. The better understanding of the clinical changes during disease progression might provide further insight into the COVID-19 pathophysiology.
. 2020 Aug 12;2020:3280908.
doi: 10.1155/2020/3280908. eCollection 2020.
Changes in the Clinical Characteristics of 62 Patients Who Died from Coronavirus Disease 2019
Jingli Chen[SUP] 1 [/SUP], Jishi Ye[SUP] 2 [/SUP], Hui Li[SUP] 3 [/SUP], Zhongyuan Xia[SUP] 2 [/SUP], Hong Yan[SUP] 1 [/SUP]
Affiliations
- PMID: 32851063
- PMCID: PMC7436351
- DOI: 10.1155/2020/3280908
Abstract
Background: Since the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in December 2019 in Wuhan, China, the virus has spread to other parts of China and across the world. Although a few studies have assessed the clinical course of coronavirus disease 2019 (COVID-19), the changes in clinical characteristics during disease progression remain unclear.
Methods: We retrospectively analyzed the clinical characteristics of 62 patients who died from COVID-19 at the Central Hospital of Wuhan between January 26 and February 17, 2020. We compared the clinical features on admission and at the last follow-up before death.
Results: Of the 62 patients with COVID-19, 41 (66%) patients were male, and 21 (34%) were female. The median age was 72 years (interquartile range (IQR), 54-88), and 45 (72.5%) patients had preexisting conditions. The median time from symptom onset to the first visit at the clinic was three days, while the median time from symptom onset to death was 18.5 days. During disease progression, the amounts of arterial gases worsened, and liver, renal, and heart dysfunction was observed. Due to the cytokine storm, infection-related biomarkers, including lactic acid, C-reactive protein, and interleukine-6, gradually worsened during hospitalization.
Conclusion: Our findings suggest that during hospitalization, many COVID-19 patients experienced multiple organ dysfunction and cytokine storm. The time from symptom onset to death was only 18.5 days, highlighting the disease's rapid progression. The better understanding of the clinical changes during disease progression might provide further insight into the COVID-19 pathophysiology.